20/20 Biolabs, Inc. Common Stock Cash Flow-to-Debt Ratio
20/20 Biolabs, Inc. Common Stock cash flow-to-debt ratio. 20/20 Biolabs, Inc. Common Stock (AIDX) has a Cash Flow-to-Debt Ratio of -0.26x as of December 2024, meaning its operating cash flow of $-536.45K could theoretically repay 0% of its total liabilities ($2.08 Million) in one year. Check earnings quality score of 20/20 Biolabs, Inc. Common Stock to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of 20/20 Biolabs, Inc. Common Stock (2016–2024)
Cash flow-to-debt ratio of 20/20 Biolabs, Inc. Common Stock from 2016 to 2024. Historical debt coverage capacity for 20/20 Biolabs, Inc. Common Stock across 9 annual periods. Check how aggressively does 20/20 Biolabs, Inc. Common Stock reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
20/20 Biolabs, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2016–2024)
20/20 Biolabs, Inc. Common Stock cash flow-to-debt ratio by year from 2016 to 2024. Year-by-year debt coverage analysis for 20/20 Biolabs, Inc. Common Stock. For the full cash flow conversion analysis, see 20/20 Biolabs, Inc. Common Stock operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.25x | $-2.60 Million | $2.08 Million | ▲ +43.8% |
| 2023 | -2.22x | $-4.63 Million | $2.08 Million | ▼ -208.9% |
| 2022 | 2.04x | $5.80 Million | $2.84 Million | ▲ +743.4% |
| 2021 | -0.32x | $-1.07 Million | $3.38 Million | ▲ +79.9% |
| 2020 | -1.58x | $-2.04 Million | $1.29 Million | ▲ +27.2% |
| 2019 | -2.17x | $-2.12 Million | $976.56K | ▼ -35.7% |
| 2018 | -1.60x | $-1.31 Million | $820.54K | ▼ -45.9% |
| 2017 | -1.10x | $-1.06 Million | $965.94K | ▲ +67.4% |
| 2016 | -3.37x | $-1.89 Million | $561.95K | — |